AI assistant
PRECISION BIOSCIENCES INC — Director's Dealing 2019
Mar 27, 2019
34491_dirs_2019-03-27_2b9ed5f1-2459-40d2-bd73-02b268309ef8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: PRECISION BIOSCIENCES INC (DTIL)
CIK: 0001357874
Period of Report: 2019-03-27
Reporting Person: Schinazi Raymond F (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series B Preferred Stock | $ | Common Stock (56102) | Indirect |
Footnotes
F1: Each share of Series B Preferred Stock is convertible at the holder's election into approximately 0.468452971537734 share of the common stock of Precision BioSciences, Inc. (the "Issuer") (on an adjusted basis, after giving effect to the 1-for-2.134686 reverse stock split effected by the Issuer in connection with its initial public offering) and has no expiration date. The Series B Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
F2: The securities reported herein are held of record by RFS Partners, LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein.